Header Logo

Connection

HUAMIN WANG to Pancreatic Neoplasms

Back to Details
This is a "connection" page, showing publications HUAMIN WANG has written about Pancreatic Neoplasms.
HUAMIN WANG
Connection Strength
4.744
Pancreatic Neoplasms
  1. Malignant Solitary Fibrous Tumor of the Pancreas. Pancreas. 2015 Aug; 44(6):988-94.
    View in: PubMed
    Score: 0.156
  2. Obesity, Intrapancreatic Fatty Infiltration, and Pancreatic Cancer. Clin Cancer Res. 2015 Aug 01; 21(15):3369-71.
    View in: PubMed
    Score: 0.153
  3. The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1. J Biol Chem. 2014 Feb 14; 289(7):4009-17.
    View in: PubMed
    Score: 0.139
  4. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol. 2014 Mar; 45(3):456-63.
    View in: PubMed
    Score: 0.137
  5. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec; 44(12):2792-8.
    View in: PubMed
    Score: 0.137
  6. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology. 2013 Dec; 63(6):841-51.
    View in: PubMed
    Score: 0.137
  7. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Jun; 44(6):1024-30.
    View in: PubMed
    Score: 0.130
  8. Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. 2013 Feb; 62(3):465-71.
    View in: PubMed
    Score: 0.129
  9. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1336-43.
    View in: PubMed
    Score: 0.125
  10. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. Ann Diagn Pathol. 2012 Oct; 16(5):427.
    View in: PubMed
    Score: 0.124
  11. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol. 2012 Apr 04; 5:15.
    View in: PubMed
    Score: 0.124
  12. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012 Apr; 36(4):552-9.
    View in: PubMed
    Score: 0.123
  13. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012 Mar; 36(3):409-17.
    View in: PubMed
    Score: 0.123
  14. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.121
  15. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012 Jan; 16(1):29-37.
    View in: PubMed
    Score: 0.120
  16. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.120
  17. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.117
  18. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2011 Feb 15; 117(4):734-43.
    View in: PubMed
    Score: 0.111
  19. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2598-604.
    View in: PubMed
    Score: 0.110
  20. High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2010 Jul 15; 16(14):3734-42.
    View in: PubMed
    Score: 0.110
  21. Metastatic adult granulosa cell tumor mimicking a benign pancreatic cyst. Ann Diagn Pathol. 2010 Dec; 14(6):457-60.
    View in: PubMed
    Score: 0.106
  22. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res. 2009 Feb 01; 69(3):1063-70.
    View in: PubMed
    Score: 0.099
  23. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008 Nov 01; 14(21):7043-9.
    View in: PubMed
    Score: 0.097
  24. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015 Oct; 39(10):1395-403.
    View in: PubMed
    Score: 0.039
  25. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep; 76(3):489-498.
    View in: PubMed
    Score: 0.039
  26. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.038
  27. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Lab Invest. 2015 Feb; 95(2):207-22.
    View in: PubMed
    Score: 0.037
  28. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.037
  29. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015 Apr; 22(4):1168-75.
    View in: PubMed
    Score: 0.037
  30. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin Cancer Res. 2014 Dec 15; 20(24):6529-40.
    View in: PubMed
    Score: 0.037
  31. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94.
    View in: PubMed
    Score: 0.037
  32. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36.
    View in: PubMed
    Score: 0.036
  33. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One. 2014; 9(7):e101452.
    View in: PubMed
    Score: 0.036
  34. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014 Jul 03; 158(1):185-197.
    View in: PubMed
    Score: 0.036
  35. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.035
  36. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014 Mar; 19(3):266-74.
    View in: PubMed
    Score: 0.035
  37. Combined targeting of STAT3/NF-?B/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1259-73.
    View in: PubMed
    Score: 0.035
  38. Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol. 2014 Feb; 38(2):147-57.
    View in: PubMed
    Score: 0.035
  39. CT imaging features of acinar cell carcinoma and its hepatic metastases. Abdom Imaging. 2013 Dec; 38(6):1383-90.
    View in: PubMed
    Score: 0.035
  40. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.035
  41. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.034
  42. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.034
  43. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2013 Dec; 145(6):1449-58.
    View in: PubMed
    Score: 0.034
  44. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Mol Med. 2013 Sep; 5(9):1322-34.
    View in: PubMed
    Score: 0.034
  45. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
    View in: PubMed
    Score: 0.034
  46. Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2013 Apr; 37(4):601-5.
    View in: PubMed
    Score: 0.033
  47. Pancreatic cancer-associated Cathepsin E as a drug activator. J Control Release. 2013 May 10; 167(3):221-7.
    View in: PubMed
    Score: 0.033
  48. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res. 2013 Feb 01; 19(3):549-59.
    View in: PubMed
    Score: 0.033
  49. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One. 2012; 7(8):e42699.
    View in: PubMed
    Score: 0.032
  50. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.031
  51. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.031
  52. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol. 2012; 10(5):e1001326.
    View in: PubMed
    Score: 0.031
  53. An NF-?B pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest. 2012 Apr; 122(4):1519-28.
    View in: PubMed
    Score: 0.031
  54. KrasG12D-induced IKK2/?/NF-?B activation by IL-1a and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Jan 17; 21(1):105-20.
    View in: PubMed
    Score: 0.030
  55. Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery. 2011 Dec; 150(6):1143-52.
    View in: PubMed
    Score: 0.030
  56. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.030
  57. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut. 2012 Sep; 61(9):1315-22.
    View in: PubMed
    Score: 0.030
  58. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011 Nov 15; 17(22):7015-23.
    View in: PubMed
    Score: 0.030
  59. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas. 2011 Aug; 40(6):815-22.
    View in: PubMed
    Score: 0.029
  60. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol. 2012 Jul; 19 Suppl 3:S395-403.
    View in: PubMed
    Score: 0.029
  61. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One. 2011; 6(6):e20636.
    View in: PubMed
    Score: 0.029
  62. KLF4a up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology. 2010 Dec; 139(6):2135-45.
    View in: PubMed
    Score: 0.028
  63. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res. 2010 Sep 01; 70(17):6824-36.
    View in: PubMed
    Score: 0.027
  64. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.027
  65. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009; 4(11):1670-80.
    View in: PubMed
    Score: 0.026
  66. Ras activity levels control the development of pancreatic diseases. Gastroenterology. 2009 Sep; 137(3):1072-82, 1082.e1-6.
    View in: PubMed
    Score: 0.025
  67. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9.
    View in: PubMed
    Score: 0.025
  68. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.025
  69. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res. 2008 Dec 15; 14(24):8052-60.
    View in: PubMed
    Score: 0.025
  70. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 2008 Oct 01; 68(19):7811-8.
    View in: PubMed
    Score: 0.024
  71. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6.
    View in: PubMed
    Score: 0.024
  72. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008 Aug 01; 68(15):6100-8.
    View in: PubMed
    Score: 0.024
  73. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
    View in: PubMed
    Score: 0.024
  74. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502.
    View in: PubMed
    Score: 0.024
  75. Current diagnosis and management of unusual pancreatic tumors. Am J Surg. 2008 Jul; 196(1):100-13.
    View in: PubMed
    Score: 0.024
  76. Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach. J Am Coll Surg. 2008 Jul; 207(1):106-20.
    View in: PubMed
    Score: 0.023
  77. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res. 2008 Apr 01; 14(7):1997-2005.
    View in: PubMed
    Score: 0.023
  78. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 2008 Mar; 36(2):178-86.
    View in: PubMed
    Score: 0.023
  79. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008 May; 15(5):1356-66.
    View in: PubMed
    Score: 0.023
  80. Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. JOP. 2008 Jan 08; 9(1):56-60.
    View in: PubMed
    Score: 0.023
  81. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer. 2007 Dec 15; 110(12):2682-90.
    View in: PubMed
    Score: 0.023
  82. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007 Jul; 246(1):52-60.
    View in: PubMed
    Score: 0.022
  83. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol. 2007 Mar; 35(3):143-7.
    View in: PubMed
    Score: 0.022
  84. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006 Nov 01; 66(21):10525-33.
    View in: PubMed
    Score: 0.021
  85. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8):1035-46.
    View in: PubMed
    Score: 0.021
  86. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep. 2013 Oct 31; 5(2):314-22.
    View in: PubMed
    Score: 0.009
  87. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
    View in: PubMed
    Score: 0.008
  88. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 2012 Feb 14; 21(2):196-211.
    View in: PubMed
    Score: 0.008
  89. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res. 2011 Feb 01; 71(3):884-94.
    View in: PubMed
    Score: 0.007
  90. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009 Jul 15; 69(14):5820-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.